Get the Daily Brief
Latest Biotech News
Benchling taps NVIDIA models — AI investors double down
Benchling integrated NVIDIA BioNeMo models and NIM microservices into its AI platform to give bench scientists direct access to protein structure prediction and other biomolecular models. The...
Bio‑Techne expands Oxford Nanopore pact — clinical nanopore assays next
Bio‑Techne extended and broadened its partnership with Oxford Nanopore to develop targeted enrichment kits and push nanopore sequencing deeper into clinical genetic testing for heritable...
SPT Labtech and 10x Genomics partner — single‑cell automation
SPT Labtech and 10x Genomics struck a strategic partnership to automate single‑cell workflows by combining SPT’s Firefly liquid handlers with 10x’s Chromium single‑cell chemistry and planned...
GoT‑Multi maps clonal evolution in FFPE — leukemia insights
Researchers introduced GoT‑Multi, a high‑throughput single‑cell multi‑omics tool that co‑detects multiple somatic genotypes and whole transcriptomes from formalin‑fixed, paraffin‑embedded (FFPE)...
FDA delays Denali review — Hunter syndrome decision pushed
The U.S. Food and Drug Administration extended its review of Denali Therapeutics’ biologics license application for tividenofusp alfa, a treatment for Hunter syndrome, by three months after...
BioCryst buys Astria to add long‑acting HAE shot: $700M deal
BioCryst Pharmaceuticals announced a cash-and-stock acquisition of Astria Therapeutics that values Astria at about $700 million. The deal transfers navenibart, a long-acting injectable plasma...
Kailera lands $600M to fast-track Zepbound‑like obesity shot: Series B lead
Kailera Therapeutics raised $600 million in a Series B round led by Bain Capital Private Equity to advance KAI‑9531 — a weekly injectable targeting the same receptors as Lilly’s Zepbound — into...
PacBio slashes cost per genome: reusable SMRT cells and new chemistry
Pacific Biosciences unveiled Sprq‑Nx chemistry and a program to allow select customers to reuse SMRT cell consumables on Revio instruments, promising up to 40% per‑genome savings for large...
Benchling embeds NVIDIA biomolecular AI: structure prediction in platform
Benchling announced integration of NVIDIA BioNeMo models and NIM microservices into its Benchling AI platform, enabling users to run OpenFold2‑based protein structure predictions and, over time,...
Bio‑Techne extends nanopore pact with Oxford Nanopore: clinical genetics focus
Bio‑Techne expanded its collaboration with Oxford Nanopore to develop and commercialize a broader portfolio of nanopore sequencing assays for inherited genetic disorders through 2032. The...
FDA delays Denali decision: three‑month extension on Hunter syndrome BLA
The FDA pushed back its target PDUFA date for Denali Therapeutics’ enzyme replacement therapy tividenofusp alfa (tivi) for Hunter syndrome by three months to April 5, 2026 after classifying an...
Novo Nordisk raises its MASH stake: efruxifermin buyout of Akero
Novo Nordisk moved to acquire Akero Therapeutics in a transaction valued at up to $5.2 billion to add efruxifermin (EFX), an FGF21 analogue now in Phase III for metabolic dysfunction‑associated...
BMS pays $1.5B for Orbital: in vivo cell therapy enters big pharma chase
Bristol Myers Squibb agreed to acquire Orbital Therapeutics for roughly $1.5 billion to secure an in‑vivo cell therapy platform targeting autoimmune disease. Orbital’s technology aims to program...
Lila Sciences ups its war chest: Nvidia joins $350M haul for AI‑driven biology
Lila Sciences expanded its Series A with an additional $115 million — including investment from Nvidia’s venture arm — bringing the startup’s haul to $350 million. Lila, founded by Flagship...
SPT Labtech and 10x Genomics automate single‑cell workflows: plug‑and‑play scale
SPT Labtech and 10x Genomics announced a strategic partnership to integrate SPT’s Firefly liquid‑handling automation with 10x’s Chromium single‑cell platform, with plans to extend to Visium...
BioCryst Pays $700M for Astria to Bulk Up HAE Portfolio
BioCryst Pharmaceuticals agreed to acquire Astria Therapeutics in a roughly $700 million cash-and-stock deal to add a long-acting injectable hereditary angioedema (HAE) candidate to its portfolio....
Kailera Raises $600M to Take Zepbound‑Like Obesity Shot Into Phase 3
Kailera Therapeutics secured $600 million in a Series B financing led by Bain Capital Private Equity to fund global Phase 3 trials of KAI‑9531, a weekly injectable that targets the same pathways...
PacBio Cuts Costs: Reusable Consumables and New Chemistry Aim at $300 Genome
Pacific Biosciences unveiled a plan to let select customers reuse its most expensive SMRT cell consumables and launched a new sequencing chemistry, Sprq‑Nx, to raise throughput and add...
FDA Extends Denali Review: Hunter Syndrome Decision Pushed Three Months
The FDA extended its review of Denali Therapeutics’ biologics license application for tividenofusp (tivi), an enzyme replacement therapy for Hunter syndrome, moving the PDUFA date three months to...
Benchling Adds NVIDIA Tools; Lila Sciences Expands Nvidia‑Backed Funding
Benchling is integrating NVIDIA BioNeMo models and NIM microservices into its Benchling AI platform to let scientists run protein structure prediction (OpenFold2) and other biomolecular AI tools...